Skip to main content
padlock icon - secure page this page is secure

DOTAP-Incorporated PEG-PLGA Nanoparticles for Efficient In Vitro and In Vivo Gene Delivery

Buy Article:

$106.34 + tax (Refund Policy)

The application of nucleic acids as therapeutic agents has been obstructed by the lack of efficient and safe systems for the delivery of the therapeutic DNA into target cells. Nanoparticle (NP) vectors based on biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid) (PLGA) polymers, especially the PEGylated ones, seem to be promising drug delivery systems but are far from being ideal gene delivery systems. Given the broad potential of PEGylated PLGA (PEG-PLGA) NPs in the biomedical applications, here, we designed and optimized a PEG-PLGA NP system by incorporating cationic lipids as the excipients for improving the gene delivery efficiency. Systemic investigation of this system by varying the type of the cationic lipids and PEG-PLGA polymers, preparation conditions, transfection conditions and cell lines was carried out, with the aim of finding a relatively efficient formulation for in vivo gene delivery. The optimized NP system showed excellent pDNA transfection efficacy both in vitro and in vivo, while much lower cytotoxicity than commercial Lipofectamine 2000 (Lip2000). The prepared system may be very useful for in vivo delivery of gene therapies to targeted cells.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: February 1, 2018

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more